Merck to Acquire OncoImmune for $425M

Share this


Merck to Acquire OncoImmune for $425M


  • Merck to acquire all outstanding shares of Oncolmmune for $425 M in cash as an upfront. Additionally- Oncolmmune will receive sales-based and contingent payments on the achievement of the regulatory milestones
  • The acquisition will give Merck control of CD24Fc which showed improvement in an interim efficacy analysis of a P-III study for the treatment of patients with severe and critical COVID-19. The acquisition is expected to be closed by the end of 2020
  • Prior to the completion of the acquisition- OncoImmune will spin-out certain rights and assets unrelated to the CD24Fc program to a new entity owned by the existing shareholders. Merck will invest $50M in the new entity

 ­ Ref: BusinessWire | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions